Physician profile
David Buchalter
NPI 1598781478
$20,138.36
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $113 · 2021: $399 · 2022: $1,415 · 2023: $1,029 · 2024: $1,960 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,840 · Travel and Lodging: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $4,840.41 |
| Travel and Lodging | $157.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyocera Medical Technologies, INC. | $13,259.43 | 2022-2025 | |
| Stryker Corporation | $2,157.74 | 2019-2025 | Insignia, Mako, Restoration |
| Encore Medical, Lp | $687.49 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $653.56 | 2024-2025 | Iovera, Zilretta, Exparel |
| Zimmer Biomet Holdings, INC. | $368.39 | 2019-2025 | Tapestry, Affixus |
| Microport Orthopedics INC | $318.33 | 2021-2022 | |
| Aesculap Implant Systems, LLC | $252.78 | 2019 | |
| Bone Support INC. | $243.30 | 2024-2025 | Cerament G, Ceramentbone Void Filler |
| Orthalign INC | $243.21 | 2020-2025 | Orthalign Plus |
| Depuy Synthes Sales INC. | $238.83 | 2021-2024 | Orthovisc, Na, Healix Knotless Peek |
| Smith+Nephew, INC. | $214.42 | 2022-2025 | Trigen Intertan, Evos, Maverick |
| Next Science LLC | $185.02 | 2025 | Xperience, Blastx |
| Sanara Medtech INC. | $180.97 | 2023 | Celleraterx |
| Davol INC. | $172.70 | 2022-2025 | |
| Southern Edge Orthopaedics, INC. | $166.05 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $161.37 | 2024-2025 | Restrata Wound Matrix |
| Djo, LLC | $123.26 | 2019-2024 | Cmf |
| Ethicon US, LLC | $89.59 | 2019-2024 | Ethicon, Surgiflo Hemostatic Matrix, Stratafix |
| Aroa Biosurgery Incorporated | $73.21 | 2024 | |
| Carbofix Orthopedics INC | $55.19 | 2023 | |
| Biocomposites INC | $50.82 | 2025 | Stimulan |
| Kci USA, INC. | $46.38 | 2022-2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Bioventus LLC | $29.63 | 2025 | Durolane |
| Vericel Corporation | $23.44 | 2024 | Maci |
| Csl Behring | $22.18 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.56 | 2025 | |
| Abbott Laboratories | $20.22 | 2024 | Eterna |
| Heraeus Medical, LLC. | $17.41 | 2024 | |
| Advanced Oxygen Therapy INC. | $15.54 | 2025 | Topical Oxygen Chamber For Extremities |
| Medtronic USA, INC. | $13.57 | 2019 | |
| Avanos Medical | $13.50 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.09 | 2019 | |
| Ossur Americas, INC. | $8.18 | 2024 | Miami J |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buchalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.